DOK1 and nonpapillary renal cell carcinoma: In a next step, combining such DOK1-targeted approaches with the currently available therapeutic regimens, such as ICIs, could augment the therapeutic window and overcome the development of drug resistance, commonly present in advanced ccRCC.